Xiaotian Zhu

Dr. Zhu brings a track record of drug discovery to Regor. Over his 20 years of industrial experience, Dr. Zhu worked in both small and large biotech companies, including Kinetix, Amgen, Ariad, Takeda and X-Chem. During his long tenure at Ariad as a Director and Senior Fellow, Dr. Zhu oversaw a research group of structural biology, computational chemistry, biochemistry and enzymology. Dr. Zhu also led a multi-disciplinary research team and discovered several preclinical and clinical candidates, such as AP788 which is an Ex20 EGFR inhibitor currently tested in phase II trial. In addition, Dr. Zhu was one of the major contributors to the discovery of two FDA approved drugs: ponatinib and brigatinib. Dr. Zhu received his Ph.D. from California Institute of Technology and Bachelor of Science from Beijing University. He was a postdoctoral fellow and an HHMI Research Associate at Columbia University.